Impact of adverse drug reaction and predictivity of quality of life status in tuberculosis.
Guo
N
N
Marra
F
F
Fitzgerald
J M
JM
Elwood
R K
RK
Marra
C A
CA
D000995:Antitubercular Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001955:British Columbia; D004977:Ethambutol / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects / Q000627:therapeutic use; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D011718:Pyrazinamide / Q000009:adverse effects / Q000627:therapeutic use; D011788:Quality of Life; D012189:Retrospective Studies; D012293:Rifampin / Q000009:adverse effects / Q000627:therapeutic use; D018434:Sickness Impact Profile; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000995:Antitubercular Agents; D011718:Pyrazinamide; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin